NCT04258189View on ClinicalTrials.gov

A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 11, 2020

Primary Completion Date

August 5, 2020

Study Completion Date

August 5, 2020

Conditions
Healthy
Interventions
DRUG

JNJ-64417184

Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04258189 - A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants | Biotech Hunter | Biotech Hunter